China’s National Medical Products Administration announced on March 2 that they have conditionally approved the registration application of a domestically made recombinant protein vaccine against Covid-19.
Jointly developed by the Institute of Microbiology under the Chinese Academy of Sciences and Anhui Zhifei Longcom Biopharmaceutical Ltd, the Zifivax vaccine will require three shots, but as it has lower production and storage requirements, it is safer and easier to scale up production. The vaccine uses purified pieces of the virus’ protein to trigger an immune response.
According to Anhui Zhifei’s analysis of data from its Phase III overseas clinical trials, by June 30, 2021, the vaccine provides a protection rate of 81.43 percent from Covid-19 seven days after completing the course of shots, and the protection rate against severe symptoms reached 92.87 percent.
According to China Daily, Anhui Zhifei’s vaccine is the third type of China’s Covid-19 vaccine to be sold overseas, following inactivated vaccines and adenovirus vector vaccines.
Old Version
